Search results
Results from the WOW.Com Content Network
The most common side effects caused by phenobarbital are dizziness, sedation, incoordination, and impaired balance. However, these adverse effects affect geriatric patients to a greater extent. [5] Concerning the adverse effects of phenobarbital after long-term usage, loss of appetite, depression, irritability, achiness in the bones, joints, or ...
Theophylline extended-release tablets in Japan. Theophylline, also known as 1,3-dimethylxanthine, is a drug that inhibits phosphodiesterase and blocks adenosine receptors. [1] It is used to treat chronic obstructive pulmonary disease (COPD) and asthma. [2] Its pharmacology is similar to other methylxanthine drugs (e.g., theobromine and caffeine ...
1 Side effects. 2 Drug interactions. 3 Synthesis. ... Majeptil is available in 10 mg tablets. [6] Side effects ... Rare but potentially serious adverse effects.
[9] [7] [10] A ratio of 5:1 theophylline to ephedrine is usually used in combinations of the drugs. [11] Later research found that the combination was no more effective for asthma than theophylline alone but produced more side effects. [9] [1] [12] [7]
In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects. [5] In February 2014, the US FDA granted an orphan drug designation to doxofylline for the treatment of bronchiectasis following the submission of an application by Alitair Pharmaceuticals, in May 2013. [6] [7] [8]
GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the average user. (Reminder that there are many of these meds now. GLP-1s ...
Remember, tadalafil 5-milligram side effects tend to be less severe than those experienced with 10- or 20-milligram dosages. Your provider may recommend adjusting your Cialis dosage if you’re ...
Side effects of thiocolchicoside can include nausea, allergy and vasovagal reactions. [15] Liver injury, pancreatitis, seizures, blood cell disorders, severe cutaneous disorders, rhabdomyolysis, and reproductive disorders have all been recorded in the French and European pharmacovigilance databases and in the periodic updates that the companies concerned submit to regulatory agencies.